[ad_1]
Source: AstraZeneca Plc
Source: AstraZeneca Plc
The University of Oxford confirmed that the Covid-19 vaccine is being developed with AstraZeneca Plc produced strong immune responses in older adults in an initial study, and key findings are expected from the final phase of trials in the coming weeks.
The results, published Thursday in The Lancet medical journal, shed more light on the Data published in recent months show that the experimental injection elicited an immune response in older people, who are at higher risk of severe disease. Researchers are still eagerly awaiting late-stage trial results that will show whether the Astra-Oxford vaccine can meet the high standard set by the leaders. Pfizer Inc. and Moderna Inc.
Shares of AstraZeneca rose 1.1% early Thursday morning in London.
The late-stage findings will follow a string of positive news on the vaccine front. Pfizer, in collaboration with BioNTech SE of Germany, It said Wednesday that a final analysis of trial data showed its Covid vaccine was 95% effective, paving the way for the company to apply for the first U.S. regulatory clearance for a coronavirus vaccine in a few days. . Modern appears equally effective.
Results from the phase 2 Oxford study show that the vaccine is better tolerated in older people and produces a similar immune response in young adults and the elderly. The study involved 560 adults, including 240 over the age of 70. That follows findings in older participants revealed last month and July data showing the vaccine elicited strong immune responses in adults ages 18 to 55. Elderly patients have been the most affected by the pandemic, with the vast majority of deaths occurring in those over 60 years of age.
“Inducing robust immune responses in older adults has been a long-standing challenge,” Angela Minassian, an Oxford researcher, wrote in a statement. “To demonstrate that the technology of this vaccine is capable of inducing these responses, in the age group with the highest risk of severe Covid-19 disease, it offers hope that the efficacy of the vaccine will be similar in young and old adults. “
Oxford expects end-stage efficacy results in the coming weeks, according to its statement.
The study shows that the vaccine causes few side effects and elicits a T-cell response that targets the virus within 14 days of the first dose and a protective antibody response within 28 days of the booster dose. , according to the report. Neutralization levels were reached 14 days after a booster vaccination in 208 of 209 recipients.
Read more: As the Covid vaccine approaches, the reasons for hope and caution: QuickTake
(Updates with actions in the third paragraph)
